Hydrogen Breath Tests

Chapter

Abstract

Bloating, flatulence, abdominal pain, and diarrhea are common complaints. Some of the patients are diagnosed as having IBS. Yet, high rate of the general population suffer from carbohydrate malabsorption that might respond to dietary change and specific treatments. Identification of these patients and adequate treatment might improve symptoms and their quality of life. Approximately 75% of the human population has a reduced ability to digest lactose after infancy. However, symptomatic malabsorption is seen in only a fraction of the population and is called lactose intolerance. Lactase deficiency can be a primary autosomal recessive condition or secondary to a disease process such as in celiac disease, gastroenteritis, and Crohn’s disease, leading to transient lactase deficiency and appearance of abdominal symptoms.

Fructose is a monosaccharide commonly found in fruits and as a sweetener. It is absorbed along the small bowel in a passive diffusion, facilitated by glucose transport protein 5 (GLUT5). Thus, fructose absorption is physiologically limited. In contrast to lactose, malabsorption of fructose tends to decrease with age.

The definition of SIBO (small intestinal bacterial overgrowth) depends on the concentration of bacteria in certain anatomical locations along the small bowel. Patients with SIBO may be clinically asymptomatic or may have symptoms that fit the diagnostic criteria of IBS. Presumed pathogenesis is mucosal injury, induced by bacteria or their toxins, or the presence of intraluminal bacteria causing malnutrition and vitamin deficiencies. In old age patients, motility disorders are probably the major cause of development of SIBO.

The diagnosis of the abovementioned conditions requires detailed medical history, dietary and lifestyle assessment, in some cases also blood and fecal tests, endoscopy and radiological imaging. Exclusion diets can be the first diagnostic modality for carbohydrate malabsorption. In patients suspected of having IBS, low short chain fermentable carbohydrates (low FODMAP) diet is considered the most successful exclusion diet.

Hydrogen and/or methane breath testing are useful, indirect, noninvasive measures to assess carbohydrate malabsorption in the gastrointestinal tract. In these tests, a measured amount of lactose or fructose are given to the patient. The unabsorbed carbohydrate is metabolized by the gastrointestinal microbiota producing hydrogen or methane which is absorbed into the bloodstream and expired via the lungs. Lactulose is used for SIBO diagnosis, as this carbohydrate is metabolized solely by the gut microbiota, a high hydrogen/methane reading of the test is diagnostic for SIBO. The tests have an excellent safety profile, but there appears to be huge individual inter- and intra-variability in the amount and the duration of gas production, that does not correlate with symptom profile or severity.

Treatment for lactose intolerance includes reduction of lactose intake. Tolerance may be induced by repeated lactose dosing due to adaptation of the intestinal flora. Compliance with a fructose-restricted diet may significantly improve symptoms of fructose intolerance, especially in a patient primarily diagnosed with IBS. The primary goal of therapy in SIBO is the treatment of any underlying disease or structural defect. Treatment of SIBO aims to modify the GI microbiota, thus many different antibiotic regimens have been advocated for use in SIBO. Recently, a locally active antibiotic—rifaximin—was used successfully in patients with SIBO. Pilot studies address the use of probiotics in SIBO. SIBO is a relapsing disease, especially when there are predisposing factors and may require repeat antibiotic use.

Keywords

Carbohydrate malabsorption Lactose intolerance Fructose intolerance SIBO IBS Hydrogen breath test Methane breath test 

References

  1. 1.
    Yang J, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11(3):262–8. e1PubMedCrossRefGoogle Scholar
  2. 2.
    Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40(9):1023–34.PubMedCrossRefGoogle Scholar
  3. 3.
  4. 4.
    Jellema P, et al. Lactose malabsorption and intolerance: a systematic review on the diagnostic value of gastrointestinal symptoms and self-reported milk intolerance. QJM. 2010;103(8):555–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Gasbarrini A, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome consensus conference. Aliment Pharmacol Ther. 2009;29(Suppl 1):1–49.PubMedGoogle Scholar
  6. 6.
    Gibson PR, et al. Review article: fructose malabsorption and the bigger picture. Aliment Pharmacol Ther. 2007;25(4):349–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Goebel-Stengel M, et al. Unclear abdominal discomfort: pivotal role of carbohydrate malabsorption. J Neurogastroenterol Motil. 2014;20(2):228–35.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Nelis GF, Vermeeren MA, Jansen W. Role of fructose-sorbitol malabsorption in the irritable bowel syndrome. Gastroenterology. 1990;99(4):1016–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Latulippe ME, Skoog SM. Fructose malabsorption and intolerance: effects of fructose with and without simultaneous glucose ingestion. Crit Rev Food Sci Nutr. 2011;51(7):583–92.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Grace E, et al. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38(7):674–88.PubMedCrossRefGoogle Scholar
  11. 11.
    Shatin R. Evolution and lactase deficiency. Gastroenterology. 1968;54(5):992.PubMedGoogle Scholar
  12. 12.
    Swallow DM. Genetics of lactase persistence and lactose intolerance. Annu Rev Genet. 2003;37:197–219.PubMedCrossRefGoogle Scholar
  13. 13.
    Welsh JD, et al. Intestinal disaccharidase activities in relation to age, race, and mucosal damage. Gastroenterology. 1978;75(5):847–55.PubMedGoogle Scholar
  14. 14.
    Swallow DM, Edward HE. The genetic polymorphism of intestinal lactase activity in adult humans. In: Scriver CR, Sly WS, et al., editors. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York: NY: McGraw-Hill; 2000.Google Scholar
  15. 15.
    Riby JE, Fujisawa T, Kretchmer N. Fructose absorption. Am J Clin Nutr. 1993;58(5 Suppl):748S–53S.PubMedGoogle Scholar
  16. 16.
    Jones HF, Butler RN, Brooks DA. Intestinal fructose transport and malabsorption in humans. Am J Physiol Gastrointest Liver Physiol. 2011;300(2):G202–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Kayano T, et al. Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6). J Biol Chem. 1990;265(22):13276–82.PubMedGoogle Scholar
  18. 18.
    Rumessen JJ, Gudmand-Hoyer E. Absorption capacity of fructose in healthy adults. Comparison with sucrose and its constituent monosaccharides. Gut. 1986;27(10):1161–8.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Rao SS, et al. Ability of the normal human small intestine to absorb fructose: evaluation by breath testing. Clin Gastroenterol Hepatol. 2007;5(8):959–63.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Jones HF, et al. Developmental changes and fructose absorption in children: effect on malabsorption testing and dietary management. Nutr Rev. 2013;71(5):300–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Wilder-Smith CH, et al. Fructose transporters GLUT5 and GLUT2 expression in adult patients with fructose intolerance. United European Gastroenterol J. 2014;2(1):14–21.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Wasserman D, et al. Molecular analysis of the fructose transporter gene (GLUT5) in isolated fructose malabsorption. J Clin Invest. 1996;98(10):2398–402.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Born P, et al. Colonic bacterial activity determines the symptoms in people with fructose-malabsorption. Hepato-Gastroenterology. 1995;42(6):778–85.PubMedGoogle Scholar
  24. 24.
    Symons P, Jones MP, Kellow JE. Symptom provocation in irritable bowel syndrome. Effects of differing doses of fructose-sorbitol. Scand J Gastroenterol. 1992;27(11):940–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Bauer TM, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Vantrappen G, et al. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59(6):1158–66.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Phillips SF, et al. Motility of the ileocolonic junction. Gut. 1988;29(3):390–406.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Ojetti V, et al. Small bowel bacterial overgrowth and type 1 diabetes. Eur Rev Med Pharmacol Sci. 2009;13(6):419–23.PubMedGoogle Scholar
  29. 29.
    Marie I, et al. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford). 2009;48(10):1314–9.CrossRefGoogle Scholar
  30. 30.
    Parodi A, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol. 2008;103(5):1257–62.PubMedCrossRefGoogle Scholar
  31. 31.
    Krishnamurthy S, et al. Jejunal diverticulosis. A heterogenous disorder caused by a variety of abnormalities of smooth muscle or myenteric plexus. Gastroenterology. 1983;85(3):538–47.PubMedGoogle Scholar
  32. 32.
    Jacobs C, et al. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37(11):1103–11.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Roland BC, et al. Small intestinal transit time is delayed in small intestinal bacterial overgrowth. J Clin Gastroenterol. 2015;49(7):571–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Paik CN, et al. The role of small intestinal bacterial overgrowth in postgastrectomy patients. Neurogastroenterol Motil. 2011;23(5):e191–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Iivonen MK, Ahola TO, Matikainen MJ. Bacterial overgrowth, intestinal transit, and nutrition after total gastrectomy. Comparison of a jejunal pouch with roux-en-Y reconstruction in a prospective random study. Scand J Gastroenterol. 1998;33(1):63–70.PubMedCrossRefGoogle Scholar
  36. 36.
    Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.PubMedCrossRefGoogle Scholar
  37. 37.
    Ratuapli SK, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol. 2012;107(5):730–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Ghoshal UC, et al. Chronic diarrhea and malabsorption due to hypogammaglobulinemia: a report on twelve patients. Indian J Gastroenterol. 2011;30(4):170–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412–9.PubMedGoogle Scholar
  40. 40.
    Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Esposito I, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13(45):6016–21.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Peralta S, et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol. 2009;15(21):2628–31.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Rana SV, et al. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion. 2012;85(3):243–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Parodi A, et al. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. J Clin Gastroenterol. 2009;43(10):962–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Lomer MC. Review article: the aetiology, diagnosis, mechanisms and clinical evidence for food intolerance. Aliment Pharmacol Ther. 2015;41(3):262–75.PubMedCrossRefGoogle Scholar
  46. 46.
    Misselwitz B, et al. Lactose malabsorption and intolerance: pathogenesis, diagnosis and treatment. United European Gastroenterol J. 2013;1(3):151–9.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med. 1995;333(1):1–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Savaiano DA, Boushey CJ, McCabe GP. Lactose intolerance symptoms assessed by meta-analysis: a grain of truth that leads to exaggeration. J Nutr. 2006;136(4):1107–13.PubMedGoogle Scholar
  49. 49.
    Shaukat A, et al. Systematic review: effective management strategies for lactose intolerance. Ann Intern Med. 2010;152(12):797–803.PubMedCrossRefGoogle Scholar
  50. 50.
    Newcomer AD, et al. Response of patients with irritable bowel syndrome and lactase deficiency using unfermented acidophilus milk. Am J Clin Nutr. 1983;38(2):257–63.PubMedGoogle Scholar
  51. 51.
    Pakdaman MN, et al. The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial. Nutr J. 2016;15(1):56.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Hertzler SR, Savaiano DA. Colonic adaptation to daily lactose feeding in lactose maldigesters reduces lactose intolerance. Am J Clin Nutr. 1996;64(2):232–6.PubMedGoogle Scholar
  53. 53.
    Briet F, et al. Improved clinical tolerance to chronic lactose ingestion in subjects with lactose intolerance: a placebo effect? Gut. 1997;41(5):632–5.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Cappello G, Marzio L. Rifaximin in patients with lactose intolerance. Dig Liver Dis. 2005;37(5):316–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Choi YK, et al. Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol. 2008;42(3):233–8.PubMedGoogle Scholar
  56. 56.
    Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol. 2010;25(2):252–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Fedewa A, Rao SS. Dietary fructose intolerance, fructan intolerance and FODMAPs. Curr Gastroenterol Rep. 2014;16(1):370.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Halmos EP, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67–75. e5PubMedCrossRefGoogle Scholar
  59. 59.
    Nasr I, et al. Effects of tegaserod and erythromycin in upper gut dysmotility: a comparative study. Indian J Gastroenterol. 2009;28(4):136–42.PubMedCrossRefGoogle Scholar
  60. 60.
    Shah SC, et al. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38(8):925–34.PubMedCrossRefGoogle Scholar
  61. 61.
    Lauritano EC, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. 2009;13(2):111–6.PubMedGoogle Scholar
  62. 62.
    Pimentel M, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32.PubMedCrossRefGoogle Scholar
  63. 63.
    Lacy BE, Chey WD, Lembo AJ. New and emerging treatment options for irritable bowel syndrome. Gastroenterol Hepatol (N Y). 2015;11(4 Suppl 2):1–19.Google Scholar
  64. 64.
    Gottlieb K, et al. Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. Aliment Pharmacol Ther. 2016;43(2):197–212.PubMedCrossRefGoogle Scholar
  65. 65.
    Triantafyllou K, Chang C, Pimentel M. Methanogens, methane and gastrointestinal motility. J Neurogastroenterol Motil. 2014;20(1):31–40.PubMedCrossRefGoogle Scholar
  66. 66.
    Barrett JS, et al. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol. 2008;14(32):5020–4.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Halmos EP, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64(1):93–100.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Neurogastroenterology and Motility Unit, Department of Gastroenterology and Liver DiseasesTel-Aviv “Sourasky” Medical CenterTel-AvivIsrael

Personalised recommendations